Kairos Pharma Files 2024 Annual Report Amendment
Ticker: KAPA · Form: 10-K/A · Filed: Apr 29, 2025 · CIK: 1962011
Sentiment: neutral
Topics: amendment, annual-report, pharmaceutical
TL;DR
Kairos Pharma amended its 2024 10-K. Check for updates.
AI Summary
Kairos Pharma, LTD. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2024. The company, incorporated in Delaware with its principal executive offices in Los Angeles, CA, operates in the Pharmaceutical Preparations sector. This amendment was filed on April 29, 2025.
Why It Matters
This filing provides updated or corrected information for investors regarding Kairos Pharma's financial performance and business operations for the 2024 fiscal year.
Risk Assessment
Risk Level: low — This is a routine amendment to an annual report, not indicating new material adverse events.
Key Numbers
- 001-42275 — SEC File Number (Identifies the company's filings with the SEC.)
- 46-2993314 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
- December 31, 2024 (date) — Fiscal year end
- April 29, 2025 (date) — Filing date
FAQ
What specific information is being amended in this 10-K/A filing?
The filing is an amendment to the Form 10-K for the fiscal year ended December 31, 2024, but the specific details of the amendments are not provided in this header information.
When was the original 10-K filed, or when was this amendment filed?
This amendment (10-K/A) was filed on April 29, 2025.
What is Kairos Pharma, LTD.'s primary business sector?
Kairos Pharma, LTD. is in the Pharmaceutical Preparations sector, SIC code 2834.
Where are Kairos Pharma, LTD.'s principal executive offices located?
The principal executive offices are located at 2355 Westwood Blvd. #139, Los Angeles, CA 90064.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 29, 2025 regarding Kairos Pharma, LTD. (KAPA).